| Code | CSB-RA896869MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to EU-103, designed for specific recognition of VSIG4 (V-Set and Immunoglobulin domain containing 4), also known as Z39Ig or CRIg (complement receptor of the immunoglobulin superfamily). VSIG4 is a type I transmembrane protein predominantly expressed on tissue-resident macrophages, where it functions as a complement receptor that binds C3b and inhibits complement activation. This protein plays critical roles in immune regulation and inflammatory responses, particularly in the tumor microenvironment where macrophage activity influences cancer progression. VSIG4 has been implicated in various pathological conditions including hepatocellular carcinoma, colorectal cancer, and inflammatory diseases, making it an important target for understanding macrophage-mediated immune modulation.
The reference antibody EU-103 has been utilized in immunological research to investigate VSIG4 expression patterns and functional roles in tissue macrophages. This biosimilar antibody serves as a valuable research tool for studying macrophage biology, complement regulation, tumor-associated macrophage phenotypes, and immune checkpoint mechanisms in various disease models and experimental systems.
There are currently no reviews for this product.